Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Tracon Pharmaceuticals, Inc. (TCON) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update San Diego, CA – August 14, 2023 – TRACON Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the second quarter ended June 30, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. “We were pleased to collect the arbitration award of $22M, the initial net proceeds of which extend our cash runway into early 2024 and past expected full accrual of the ENVASARC pivotal trial,” said Charles Th..."
03/08/2023 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update"
11/14/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
03/15/2022 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update - Announced FDA Approval of Amended ENVASARC Protocol, ENVASARC Interim Efficacy Data on Track for 2H22"
11/03/2021 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
08/11/2021 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update"
05/05/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update"
08/05/2020 8-K Quarterly results
05/13/2020 8-K Quarterly results
02/27/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update"
08/07/2019 8-K Quarterly results
05/14/2019 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update"
02/28/2019 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update"
08/08/2018 8-K Quarterly results
Docs: "bout TRC253"
05/09/2018 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update"
11/07/2017 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update"
08/08/2017 8-K Quarterly results
05/10/2017 8-K Form 8-K - Current report
02/28/2017 8-K Form 8-K - Current report
08/10/2016 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update"
05/11/2016 8-K Form 8-K - Current report
02/18/2016 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Corporate Update"
11/03/2015 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Third Quarter 2015 Results and Provides Corporate Update"
08/05/2015 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update"
05/13/2015 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update Phase 2 Clinical Trials of TRC105 continue to enroll patients Cash balance of $65.3 million at March 31, 2015 San Diego, CA — May 13, 2015 — TRACON Pharmaceuticals , a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, today announced its financial results for the first quarter ended March 31, 2015. First Quarter 2015 and Recent Corporate Highlights"
03/10/2015 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports 2014 Year-End Financial Results and Recent Corporate Highlights"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy